Ocular Surface Disease

Hear what is new in the world of ocular surface disease, and what's coming down the pipeline.

Results of the BRIO-I study, the first of 2 phase 3 clinical trials of Brimochol PF, a topical, fixed-dose combination for the treatment of presbyopia, have recently been released.

Ben Bergo, CEO of Visus, shares data from the company's pivotal phase 3 BRIO-1 trial, as well as answers questions about Brimochol PF.

Easy-to-use modality offers exciting benefits for patients.

Combination therapy may reduce adverse events related to corticosteroids alone.

Set your young patients—and their caregivers—up for success in treatment.

According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution) is the first prescription eye drop that targets tear evaporation.

Dual-purpose therapeutics help patients with both conditions.

The organization says to stop using Dr. Berne’s and LightEyez MSM drops immediately due to bacterial contamination, fungal contamination, or both.

This NDA transfer marks the fourth FDA-approved ophthalmic product purchased by Harrow earlier in 2023 now commercially available in the US.

Pediatric keratoconus is often more challenging to diagnose, resulting in treatment delay and vision loss.

Combining simple and advanced methods can lead to optimal patient outcomes.

Proper management results in better expectations, outcomes for patients.

The company has entered a definitive agreement with Novartis to acquire Xiidra (liftegrast ophthalmic solution 5%), representing a significant opportunity for growth in prescription dry eye.

Horizon Therapeutics announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA as the first and only medicine approved in Brazil for treatment of thyroid eye disease.

Erich A. Hinel, OD, MS, FAAO, Dipl ABO, discusses the use of 3-layer amniotic membrames to treat severe keratoconjunctivitis sicca, severe dry eye, and ocular surface disease.

Harmin Chima, OD, met with Optometry Times to discuss treatment options for ocular surface disease with Biovance's 3-layer amniotic membrane graft.

Mile Brujic, OD, FAAO, shares an overview of his AOA 2023 presentation, which covered 12 new treatments all optometrists should know about.

Mile Brujic, OD, FAAO, shares an overview of his AOA 2023 presentation that discussed the pharmaceutical treatment of anterior segment inflammatory conditions.

Jessilin Quint, OD, MBA, MS, FAAO, shares the latest and greatest in the world of dry eye, from new technology to how clinicians can start in on dry eye therapy today.

The evolution opens doors for the treatment of neurotrophic keratitis and beyond.

Mydcombi is the first FDA-approved, fixed-combination of tropicamide and phenylephrine for the reversal of mydriasis.

Selina McGee, OD, FAAO, Dipl ABO, shares highlights from her featured symposium, "Thyroid eye disease: The masquerading eye disorder," which she co-presented during the 2023 Controversies in Modern Eye Care meeting.

Laura Periman, MD, breaks down some myths and controversies in the cosmetic world in her presentation, "Ocular toxins everywhere and in everything," presented at the Controversies in Modern Eye Care meeting.

Several eye conditions may benefit from membrane application.

Help patients establish a daily eye care routine like the one they have for oral health.

The authors conducted a prospective non-interventional study in which a self-questionnaire was used to evaluate the ocular symptoms and medical background of patients with KC and OSD who engage in chronic eye rubbing.

The ones you should seek out—and avoid.

A look back on what's happened in optometry during the week of March 3-March 9.

Treatment should be adjusted based on disease severity.